Economic evaluations of pharmacogenetic and genomic screening programs: Update of the literature

Drug Development Research

Volumn 71, Issue 8, 2010, Pages 492-501

  Vegter, Stefan ^a   Jansen, Esther ^a   Postma, Maarten J ^a   Boersma, Cornelis ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

economics; literature review; pharmacogenetics; pharmacogenomics

Indexed keywords

ABACAVIR; ALPHA ADDUCIN; AMFEBUTAMONE; AMINOGLYCOSIDE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; AZATHIOPRINE; BLOOD CLOTTING FACTOR 5; CLOZAPINE; COUMARIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE 2 RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA B ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; WARFARIN;

AWARENESS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DNA POLYMORPHISM; ECONOMIC EVALUATION; FUNDING; GENETIC SCREENING; GENOTYPE; HUMAN; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; SENSITIVITY ANALYSIS; THERAPY EFFECT;

EID: 78651067418     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20424     Document Type: Review

References (59)

1. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, et al. 2007. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116: 2563-2570.
2. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, Neumann PJ,. 2006. Bias in published cost effectiveness studies: systematic review. BMJ 332: 699-703.
3. Blank PR, Schwenkglenks M, Moch H, Szucs TD,. 2010. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat 124: 497-507.
4. Chou WH, Yan FX, de LJ, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, et al. 2000. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20: 246-251.
5. Cosler LE, Lyman GH,. 2009. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest 27: 953-959.
6. Costa-Scharplatz M, van Asselt AD, Bachmann LM, Kessels AG, Severens JL,. 2007. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. Pharmacogenet Genom 17: 359-368.
7. Dendukuri N, Khetani K, McIsaac M, Brophy J,. 2007. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. Can Med Assoc J 176: 1429-1434. (Pubitemid 46762020)
8. Dervieux T, Bala MV,. 2006. Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics 7: 1175-1184.
9. Desta Z, Zhao X, Shin JG, Flockhart DA,. 2002. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41: 913-958.
10. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GJ,. 2005. Methods for the economic evaluation of health care programs. Oxford: Oxford University Press.
11. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ,. 2005. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 100: 2239-2247.
12. Eckman MH, Rosand J, Greenberg SM, Gage BF,. 2009. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 150: 73-83.
13. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC,. 2004. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22: 854-863.
14. Farrall M, Morris AP,. 2005. Gearing up for genome-wide gene-association studies. Hum Mol Genet 14 (Special issue2): R157-R162.
15. FDA. 2006. Terminology in Pharmacogenomics. ICH E-15 Pharmacogenomics EWG.
16. FDA. 2007. FDA approves updated warfarin prescribing information. Available at:. Accessed June 21, 2010.
17. Flowers CR, Veenstra D,. 2004. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 22: 481-493.
18. Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K, et al. 2007. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 81: 521-528.
19. Gold HT, Hall MJ, Blinder V, Schackman BR,. 2009. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 115: 3858-3867.
20. Goldstein DB, Tate SK, Sisodiya SM,. 2003. Pharmacogenetics goes genomic. Nat Rev Genet 4: 937-947.
21. Hopkins MM, Ibarreta D, Gaisser S, Enzing CM, Ryan J, Martin PA, Lewis G, Detmar S, van den Akker-van Marle ME, Hedgecoe AM, et al. 2006. Putting pharmacogenetics into practice. Nat Biotechnol 24: 403-410.
22. *5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14: 335-342.
23. International Society for Pharmacoeconomics and Outcomes R. 2010. Pharmacoeconomic guidelines around the world. Available at:.
24. Kim SK, Jun JB, El-Sohemy A, Bae SC,. 2006. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 33: 1266-1274.
25. Lehmann DF, Medicis JJ, Franklin PD,. 2003. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. J Clin Pharmacol 43: 1316-1323.
26. Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J,. 2008a. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 19: 487-495.
27. Lidgren M, Wilking N, Jonsson B, Rehnberg C,. 2008b. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 47: 1018-1028.
28. Maitland-van der Zee AH, Klungel OH, Stricker BH, Veenstra DL, Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, van Duijn CM, de BA,. 2004. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics 14: 53-60.
29. Marra CA, Esdaile JM, Anis AH,. 2002. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 29: 2507-2512.
30. Meckley LM, Veenstra DL,. 2006. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genom 16: 139-147.
31. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL,. 2008. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 100: 229-239.
32. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL,. 2010. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28: 61-74.
33. Morelle M, Hasle E, Treilleux I, Michot JP, Bachelot T, Penault-Llorca F, Carrere MO,. 2006. Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. Int J Technol Assess Health Care 22: 396-401.
34. Oh KT, Anis AH, Bae SC,. 2004. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxf) 43: 156-163.
35. Patrick AR, Avorn J, Choudhry NK,. 2009. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2: 429-436.
36. Payne K, Newman WG, Gurwitz D, Ibarreta D, Phillips KA,. 2009. TPMT testing in azathioprine: cost-effective use of healthcare resources? Personal Med 6: 103-113.
37. Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, Wang PS,. 2005. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 25: 427-434.
38. Perlis RH, Patrick A, Smoller JW, Wang PS,. 2009. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34: 2227-2236.
39. Phillips KA, Van Bebber SL,. 2004. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5: 1139-1149.
40. Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, Clark DW, Hansen P,. 2006. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 24: 767-781.
41. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA,. 2005. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 41: 1316-1323.
42. *5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22: 2025-2033.
43. Schalekamp T, Boink GJ, Visser LE, Stricker BH, de BA, Klungel OH,. 2006. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther 79: 511-520.
44. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F,. 2005. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329-2333.
45. Sendi P, Gunthard HF, Simcock M, Ledergerber B, Schupbach J, Battegay M,. 2007. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS One 2: e173.
46. Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB,. 2009. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 27: 341-354.
47. Smith KJ, Monsef BS, Ragni MV,. 2008. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Thromb Haemost 100: 447-452.
48. Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, Guchelaar HJ,. 2007. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 4: e209.
49. Tavadia SM, Mydlarski PR, Reis MD, Mittmann N, Pinkerton PH, Shear N, Sauder DN,. 2000. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 42: 628-632.
50. van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez de ME, Ibarreta D,. 2006. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7: 783-792.
51. Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C,. 2007. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med 9: 695-704.
52. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ,. 2008. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 26: 569-587.
53. Vegter S, Perna A, Hiddema W, Ruggenenti P, Remuzzi G, Navis G, Postma MJ,. 2009. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenet Genom 19: 695-703.
54. Walley T, Haycox A,. 1997. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol 43: 343-348.
55. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA,. 2001. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med 134: 440-450.
56. Welton NJ, Johnstone EC, David SP, Munafo MR,. 2008. A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res 10: 231-240.
57. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR,. 2004. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 20: 593-599.
58. You JH, Chan FW, Wong RS, Cheng G,. 2004. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapya-a decision analysis. Thromb Haemost 92: 590-597.
59. You JH, Tsui KK, Wong RS, Cheng G,. 2009. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther 86: 540-547.